COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) ₪ / shares in Units, € in Thousands, ₪ in Thousands, $ in Thousands |
12 Months Ended | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 07, 2025
USD ($)
|
Jun. 07, 2025
ILS (₪)
|
May 10, 2024
EUR (€)
|
Nov. 29, 2023
ILS (₪)
|
Sep. 30, 2023
USD ($)
|
Jun. 08, 2022
USD ($)
|
Jun. 08, 2022
ILS (₪)
₪ / shares
shares
|
Dec. 31, 2025
USD ($)
shares
|
Dec. 31, 2025
ILS (₪)
|
Dec. 31, 2024
USD ($)
shares
|
Dec. 31, 2024
ILS (₪)
|
Dec. 31, 2023
ILS (₪)
|
Dec. 31, 2021 |
Dec. 31, 2025
ILS (₪)
shares
|
Dec. 31, 2024
ILS (₪)
shares
|
Dec. 31, 2023
USD ($)
|
Dec. 31, 2023
ILS (₪)
|
Sep. 30, 2023
₪ / shares
shares
|
Dec. 31, 2022
ILS (₪)
|
|
| IfrsStatementLineItems [Line Items] | |||||||||||||||||||
| Allocated number of share | shares | 6,502,844,000 | 6,271,625,000 | 6,502,844,000 | 6,271,625,000 | |||||||||||||||
| Capital raised | $ 3,164 | ₪ 10,092 | ₪ 10,968 | $ 8,000 | |||||||||||||||
| Description of leasing arrangements | The Distributor committed to placing an initial order of 20,000 Pulsenmore ES units, of which 5,000 units were supplied in 2022, and the remaining 15,000 units (including 10,000 iOS-compatible devices) were scheduled for delivery in 2023. | The Distributor committed to placing an initial order of 20,000 Pulsenmore ES units, of which 5,000 units were supplied in 2022, and the remaining 15,000 units (including 10,000 iOS-compatible devices) were scheduled for delivery in 2023. | |||||||||||||||||
| Cost | $ 1,988 | ₪ 6,342 | ₪ 6,084 | ₪ 3,987 | |||||||||||||||
| Interest payable | ₪ 6 | ||||||||||||||||||
| Interest rate | 300.00% | 300.00% | |||||||||||||||||
| Description of cancel purchase order | Distributor canceled its purchase order for 15,000 units, citing non-compatibility with iOS. | ||||||||||||||||||
| Investment proceeds | ₪ 70,096 | ||||||||||||||||||
| Share issued | $ 26,048 | $ 30,373 | ₪ 83,090 | ₪ 96,887 | ₪ 132,232 | ₪ 187,518 | |||||||||||||
| Total Transaction Costs | 782 | ||||||||||||||||||
| Equity allocated | 538 | ||||||||||||||||||
| Comprehensive loss | 244 | ||||||||||||||||||
| Losses on change in fair value of derivatives | 15,595 | ||||||||||||||||||
| Contract term | 7 years | 7 years | |||||||||||||||||
| Revenues | $ 12,547 | ₪ 40,024 | 9,661 | ₪ 6,188 | |||||||||||||||
| Financial value | € | € 400 | ||||||||||||||||||
| Collaboration agreement term | 4 years | ||||||||||||||||||
| Grant receive | 1,144 | 3,650 | 907 | ||||||||||||||||
| Royalty expense | 530 | 1,690 | $ 323 | 1,029 | |||||||||||||||
| GEHC [member] | |||||||||||||||||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||||||
| Proceeds from related parties | 1,000 | 3,371 | |||||||||||||||||
| LLI components [member] | |||||||||||||||||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||||||
| Cost | $ 909 | ₪ 2,900 | |||||||||||||||||
| Second year agreement [member] | |||||||||||||||||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||||||
| Description of leasing arrangements | the Distributor had the option to place an order for 50,000 more units in the second year of the agreement. | the Distributor had the option to place an order for 50,000 more units in the second year of the agreement. | |||||||||||||||||
| Investment agreement [member] | |||||||||||||||||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||||||
| Share issued | 51,709 | ||||||||||||||||||
| Contigent forward contract [member] | |||||||||||||||||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||||||
| Derivative assets | 5,070 | ||||||||||||||||||
| Distribution agreement [member] | |||||||||||||||||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||||||
| Customer contract liability | ₪ 23,457 | ||||||||||||||||||
| Settlement related revenue [member] | |||||||||||||||||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||||||
| Revenues | $ 7,333 | ₪ 23,392 | $ 2,200 | ₪ 7,100 | |||||||||||||||
| GE healthcare global holdings [member] | |||||||||||||||||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||||||
| Allocated number of share | shares | 449,178 | 449,178 | |||||||||||||||||
| Nominal value | ₪ / shares | ₪ 0.00032 | ₪ 0.00032 | |||||||||||||||||
| Investment | $ 21,000 | $ 21,000 | ₪ 70,096 | ||||||||||||||||
| Israel innovation authority [member] | |||||||||||||||||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||||||
| Royalty due | 4,898 | ₪ 15,626 | |||||||||||||||||
| Royalty expense | $ 3,007 | ₪ 9,591 | ₪ 7,029 | ||||||||||||||||
| Koril [member] | |||||||||||||||||||
| IfrsStatementLineItems [Line Items] | |||||||||||||||||||
| Royalty rate | 2.50% | ||||||||||||||||||